NCT03876314 (PAAD-2) is a NA clinical trial of Physical Activity Condition in Healthy, sponsored by University of North Carolina, Greensboro.

Who is sponsoring NCT03876314?

NCT03876314 is sponsored by University of North Carolina, Greensboro.

What drugs are being tested in NCT03876314?

Interventions in NCT03876314: Physical Activity Condition.

What condition does NCT03876314 study?

NCT03876314 studies Healthy, Dementia, Alzheimer Disease, Physical Activity.

Is NCT03876314 still recruiting?

NCT03876314 is currently completed. Last updated 3 April 2025.

Last reviewed 2025-04-03 · How we verify

NCT03876314: PAAD-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Physical Activity, Alzheimer's Disease and Cognition Relative to APOE Genotype

Completed NA Last updated 3 April 2025

What this trial tests

NA trial testing Physical Activity Condition in Healthy in 180 participants. Completed in 21 December 2024.

Timeline

23 May 2019

Primary endpoint
21 December 2024

21 December 2024

Quick facts

Lead sponsor	University of North Carolina, Greensboro
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	180
Start date	23 May 2019
Primary completion	21 December 2024
Estimated completion	21 December 2024
Sites	1 location across United States

Drugs / interventions tested

Physical Activity Condition

Conditions studied

Healthy — all drugs for Healthy →
Dementia — all drugs for Dementia →
Alzheimer Disease — all drugs for Alzheimer Disease →
Physical Activity — all drugs for Physical Activity →

Sponsor

University of North Carolina, Greensboro

Who can join

Adults 40 to 65, any sex, with Healthy or Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Physical activity and Alzheimer's disease (PAAD-2) is a randomized control trial that will assess the effects of exercise on middle-aged (40-65 years) cognitively normal adults who have a heightened risk of Alzheimer's disease (AD) due to family history (FH+). The investigators will also assess the extent to which this effect is moderated by apolipoprotein epsilon-4 (APOE4) carrier status, and will gather critical new experimental evidence on the use of physical activity to improve cognitive performance by persons at the greatest risk of Alzheimer's disease.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Type 3 diabetes and metabolic reprogramming of brain neurons: causes and therapeutic strategies.
Meng X, Zhang H, Zhao Z, Li S, et al · · 2025 · cited 19× · PMID 39966707 · DOI 10.1186/s10020-025-01101-z
The effect of physical activity on cognition relative to APOE genotype (PAAD-2): study protocol for a phase II randomized control trial.
Park KS, Ganesh AB, Berry NT, Mobley YP, et al · · 2020 · cited 5× · PMID 32503473 · DOI 10.1186/s12883-020-01732-1
An innovative protocol for the artificial speech-directed, contactless administration of laboratory-based comprehensive cognitive assessments: PAAD-2 trial management during the COVID-19 pandemic.
Park KS, Etnier JL. · · 2021 · cited 2× · PMID 34217888 · DOI 10.1016/j.cct.2021.106500
APOE-ε4 moderates the association between diet quality and executive function in middle-aged women at increased risk for Alzheimer’s disease
Wessinger C, Park K, DuBois S, Wideman L, et al · · 2026
Sleep Quality Moderates Age-Related Decline in Hippocampal-Dependent Memory in Midlife Adults
· 2025
Full GSA 2025 Abstract Book PDF
· 2025

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other University of North Carolina, Greensboro trials

Trials by the same sponsor.

NCT06921382 — Breastfeeding Intervention to Prevent Obesity Among Children · NA · recruiting
NCT06364189 — Inspiring Seniors Toward Exercise Promotion · NA · completed
NCT05454293 — One Talk at a Time: A Racial-ethnic Socialization Intervention for Diverse Families · NA · unknown
NCT05462977 — Rhythmically Entrained Exercise in Community-Dwelling Older Adults · NA · completed
NCT05226039 — The Effects of a Single Bout of Aerobic Exercise on Cognition: The Moderating Role of Age · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03876314 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Greensboro
Last refreshed: 3 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03876314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing